Table 4. Univariate and multivariate COX analyses for late RFS of HCC patients.
| Variables | N=111 | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Gender (female/male) | 15/96 | 0.464 (0.110–1.955) | 0.296 | |||
| Age, years (>50/≤50) | 52/59 | 1.301 (0.641–2.644) | 0.466 | |||
| Smoke (yes/no) | 27/84 | 1.535 (0.704–3.348) | 0.281 | |||
| Drink (yes/no) | 16/95 | 1.476 (0.604–3.607) | 0.393 | |||
| Diabetes (yes/no) | 4/107 | 0.408 (0.055–3.025) | 0.380 | |||
| Cirrhosis (yes/no) | 72/39 | 1.285 (0.591–2.793) | 0.527 | |||
| Ascites (yes/no) | 9/102 | 0.543 (0.074–4.010) | 0.550 | |||
| Tumor diameter, cm (>5/≤5) | 28/83 | 1.836 (0.866–3.891) | 0.113 | |||
| Tumor number (multiple/single) | 18/93 | 4.333 (2.038–9.216) | <0.001 | 4.868 (2.264–10.467) | <0.001 | |
| Vascular invasion (yes/no) | 27/84 | 1.651 (0.776–3.511) | 0.193 | |||
| Child-Pugh grade (B/A) | 8/103 | 3.681 (1.372–9.876) | 0.010 | 2.834 (1.007–7.970) | 0.048 | |
| MELD score (>2/≤2) | 87/24 | 1.221 (0.465–3.206) | 0.685 | |||
| BCLC stage (B-C/0~A) | 48/63 | 2.021 (0.982–4.160) | 0.056 | – | – | |
| Pathological differentiation (poor-moderate/well) | 78/33 | 1.089 (0.514–2.306) | 0.824 | |||
| AFP, ng/mL (>400/≤400) | 26/85 | 0.556 (0.213–1.449) | 0.229 | |||
| HBV-DNA, copies/mL (>1,000/≤1,000) | 46/65 | 0.973 (0.474–1.997) | 0.940 | |||
| Fibrinogen, g/mL (>3.52/≤3.52) | 19/92 | 2.134 (0.982–4.638) | 0.056 | – | – | |
| NLR (>1.92/≤1.92) | 47/64 | 1.062 (0.519–2.173) | 0.869 | |||
| dNLR (≤2.02/>2.02) | 78/33 | 1.048 (0.447–2.455) | 0.915 | |||
| PLR (>60.28/≤60.28) | 97/14 | 0.648 (0.247–1.700) | 0.378 | |||
| LMR (≤3.84/>3.84) | 42/69 | 1.536 (0.753–3.134) | 0.238 | |||
| GPR (>0.33/≤0.33) | 53/58 | 3.109 (1.411–6.853) | 0.005 | – | – | |
| SII (>289.28/≤289.28) | 53/58 | 0.990 (0.485–2.022) | 0.979 | |||
| PNI (≤47.6/>47.6) | 36/75 | 1.939 (0.954–3.943) | 0.067 | – | – | |
| APRI (>0.17/≤0.17) | 71/40 | 2.163 (0.882–5.302) | 0.092 | – | – | |
| ANRI (>9.39/≤9.39) | 70/41 | 1.414 (0.648–3.088) | 0.384 | |||
| ALRI (>25.69/≤25.69) | 45/66 | 1.165 (0.572–2.374) | 0.674 | |||
| ALBI (>−2.79/≤−2.79) | 58/53 | 2.963 (1.310–6.705) | 0.009 | – | – | |
| FIB-4 (>1.46/≤1.46) | 66/45 | 2.412 (0.987–5.894) | 0.053 | – | – | |
| S-index (>0.25/≤0.25) | 41/70 | 3.138 (1.511–6.516) | 0.002 | 3.074 (1.439–6.565) | 0.004 | |
MELD, Model for End-stage Liver Disease; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; HBV, hepatitis B virus; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; GPR, gamma-glutamyl transpeptidase-to-platelet ratio; SII, systemic immune-inflammation index; PNI, prognostic nutritional index; APRI, aspartate transaminase-to-platelet count ratio index; ANRI, aspartate transaminase-to-neutrophil ratio index; ALRI, aspartate transaminase-to-lymphocyte ratio index; ALBI, albumin-bilirubin; FIB-4, fibrosis index based on the four factors; RFS, recurrence-free survival.